Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675957 | 0.91 | MCHR1 (0.57) | TRPV1MCHR1NOTUMMEN1KMT2A | |
| SCHEMBL13675951 | 0.89 | MCHR1 (0.64) | TRPV1MCHR1 | |
| SCHEMBL13676073 | 0.86 | TRPV1 (0.60) | TRPV1MCHR1NOTUM | |
| SCHEMBL13676175 | 0.86 | P2RY14 (0.53) | TRPV1P2RY14MCHR1NOTUMMEN1 | |
| SCHEMBL13675972 | 0.83 | TRPV1 (0.62) | TRPV1MCHR1MEN1KMT2APLAU | |
| SCHEMBL22590471 | 0.81 | P2RY14 (0.59) | TRPV1P2RY14NOTUMMEN1KMT2A | |
| SCHEMBL4427327 | 0.81 | MEN1 (0.73) | TRPV1MEN1KMT2A | |
| SCHEMBL13676206 | 0.80 | MCHR1 (0.48) | TRPV1P2RY14MCHR1NOTUMMEN1 | |
| SCHEMBL22590411 | 0.80 | P2RY14 (0.62) | TRPV1P2RY14NOTUMMEN1KMT2A | |
| SCHEMBL846968 | 0.79 | TRPV1 (0.67) | TRPV1NOTUMMEN1KMT2AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1780196-A2 | Pyridine derivatives for use as vanilloid receptor ligands | Amgen, Inc (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885P2RY14 544/4885MCHR1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.